Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jan Liebelt is active.

Publication


Featured researches published by Jan Liebelt.


American Journal of Medical Genetics Part A | 2003

X-linked Opitz syndrome: Novel mutations in the MID1 gene and redefinition of the clinical spectrum

Francesca De Falco; Silvia Cainarca; Grazia Andolfi; Rosa Ferrentino; Caterina Berti; Germán Rodríguez Criado; Olaf Rittinger; Nick Dennis; Sylvie Odent; Amit Rastogi; Jan Liebelt; David Chitayat; Robin M. Winter; Harindar Jawanda; Andrea Ballabio; Brunella Franco; Germana Meroni

Opitz (or G/BBB) syndrome is a pleiotropic genetic disorder characterized by hypertelorism, hypospadias, and additional midline defects. This syndrome is heterogeneous with an X‐linked (XLOS) and an autosomal dominant (ADOS) form. The gene implicated in the XLOS form, MID1, encodes a protein containing a RING‐Bbox‐Coiled‐coil motif belonging to the tripartite motif (TRIM) family. To further clarify the molecular basis of XLOS, we have undertaken mutation analysis of the MID1 gene in patients with Opitz syndrome (OS). We found novel mutations in 11 of 63 male individuals referred to us as sporadic or familial X‐linked OS cases. The mutations are scattered throughout the gene, although more are represented in the 3′ region. By reviewing all the MID1‐mutated OS patients so far described, we confirmed that hypertelorism and hypospadias are the most frequent manifestations, being present in almost every XLOS individual. However, it is clear that laryngo‐tracheo‐esophageal (LTE) defects are also common anomalies, being manifested by all MID1‐mutated male patients. Congenital heart and anal abnormalities are less frequent than reported in literature. In addition, we can include limb defects in the OS clinical synopsis as we found a MID1‐mutated patient showing syndactyly. The low frequency of mutations in MID1 and the high variability of the phenotype suggest the involvement of other genes in the OS phenotype.


Nature Genetics | 2017

Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases

Holly A.F. Stessman; Bo Xiong; Bradley P. Coe; Tianyun Wang; Kendra Hoekzema; Michaela Fenckova; Malin Kvarnung; Jennifer Gerdts; Sandy Trinh; Nele Cosemans; Laura Vives; Janice Lin; Tychele N. Turner; Gijs W.E. Santen; Claudia Ruivenkamp; Marjolein Kriek; Arie van Haeringen; Emmelien Aten; Kathryn Friend; Jan Liebelt; Christopher Barnett; Eric Haan; Marie Shaw; Jozef Gecz; Britt Marie Anderlid; Ann Nordgren; Anna Lindstrand; Charles E. Schwartz; R. Frank Kooy; Geert Vandeweyer

Gene-disruptive mutations contribute to the biology of neurodevelopmental disorders (NDDs), but most of the related pathogenic genes are not known. We sequenced 208 candidate genes from >11,730 cases and >2,867 controls. We identified 91 genes, including 38 new NDD genes, with an excess of de novo mutations or private disruptive mutations in 5.7% of cases. Drosophila functional assays revealed a subset with increased involvement in NDDs. We identified 25 genes showing a bias for autism versus intellectual disability and highlighted a network associated with high-functioning autism (full-scale IQ >100). Clinical follow-up for NAA15, KMT5B, and ASH1L highlighted new syndromic and nonsyndromic forms of disease.


Clinical Genetics | 2014

Coffin–Siris syndrome is a SWI/SNF complex disorder

Yoshinori Tsurusaki; Nobuhiko Okamoto; Hirofumi Ohashi; Seiji Mizuno; Naomichi Matsumoto; Yoshio Makita; M. Fukuda; Bertrand Isidor; J. Perrier; S. Aggarwal; A.B. Dalal; Adila Al-Kindy; Jan Liebelt; David Mowat; Mitsuko Nakashima; Hirotomo Saitsu; Noriko Miyake

Coffin–Siris syndrome (CSS) is a congenital disorder characterized by intellectual disability, growth deficiency, microcephaly, coarse facial features, and hypoplastic or absent fifth fingernails and/or toenails. We previously reported that five genes are mutated in CSS, all of which encode subunits of the switch/sucrose non‐fermenting (SWI/SNF) ATP‐dependent chromatin‐remodeling complex: SMARCB1, SMARCA4, SMARCE1, ARID1A, and ARID1B. In this study, we examined 49 newly recruited CSS‐suspected patients, and re‐examined three patients who did not show any mutations (using high‐resolution melting analysis) in the previous study, by whole‐exome sequencing or targeted resequencing. We found that SMARCB1, SMARCA4, or ARID1B were mutated in 20 patients. By examining available parental samples, we ascertained that 17 occurred de novo. All mutations in SMARCB1 and SMARCA4 were non‐truncating (missense or in‐frame deletion) whereas those in ARID1B were all truncating (nonsense or frameshift deletion/insertion) in this study as in our previous study. Our data further support that CSS is a SWI/SNF complex disorder.


Clinical Genetics | 2007

Familial 22q11.2 duplication: a three-generation family with a 3-Mb duplication and a familial 1.5-Mb duplication

Sui Yu; K Cox; Kathryn Friend; S Smith; R Buchheim; Sharon M. Bain; Jan Liebelt; Elizabeth Thompson; Drago Bratkovic

We report two familial cases of 22q11.2 duplication detected using multiplex ligation‐dependent probe amplification (MLPA). In the first case, eight individuals from a three‐generation family were found to carry a 3‐Mb 22q11.2 duplication. The individuals carrying the duplication show phenotypic variation. This phenotypic variation includes heart defect (1 in 8 individuals, 1/8), submucous cleft palate (2/8), intellectual disability (2/8), speech delay (2/8), behaviour problems (3/8) and brachydactyly (3/8). In the second case, a 1.5‐Mb 22q11.2 duplication was detected in a neonate and her normal mother. The neonate presented with severe laryngomalacia causing intermittent stridor. Cranial ultrasound showed small subependymal cysts bilaterally. There was no heart defect or cleft palate, her chest X ray and renal ultrasound were normal. Review at 2 months of age revealed normal growth and development. Our findings broaden the understanding of 22q11.2 duplication syndrome and demonstrate that MLPA is sensitive for detection and sizing of 22q11.2 microduplications.


British Journal of Ophthalmology | 2006

Nail-patella syndrome and its association with glaucoma: a review of eight families

Z. Mimiwati; David A. Mackey; Jamie E. Craig; Jane R. MacKinnon; Julian L Rait; Jan Liebelt; R. Ayala-Lugo; Douglas Vollrath; Julia E. Richards

Background: Nail-patella syndrome (NPS) is a rare autosomal dominant syndrome, characterised by dysplasia of the nails, patellae, elbows and iliac horns. Mutations in the LMX1B gene were found in four North American families in whom glaucoma cosegregated with NPS. Aims: To investigate the association of glaucoma with NPS in Australian families and to determine how common NPS is in Australia. Methods: One family with NPS and glaucoma was identified from the Glaucoma Inheritance Study in Tasmania. A further 18 index cases of NPS were identified from the genetics database for southeastern Australia. Eight of these pedigrees were available for comprehensive glaucoma examination on available family members. DNA was sequenced for mutations in LMX1B. Results: In total, 52 living cases of NPS were identified suggesting a minimum prevalence of at least 1 in 100 000. 32 subjects from eight NPS pedigrees (four familial and four sporadic cases) were examined. 14 subjects had NPS alone. 4 subjects had NPS and glaucoma or ocular hypertension. Five pedigrees with NPS had a reported family history of glaucoma, although some of these people with glaucoma did not have NPS. LMX1B mutations were identified in 5 of the 8 index cases—three sporadic and two familial. Two of the six (33%) participants over 40 years of age had developed glaucoma, showing increased risk of glaucoma in NPS. Conclusion: Patients with NPS should be examined regularly for glaucoma. However, because the families with NPS are ascertained primarily from young probands or probands who are isolated cases, the exact level of risk is unclear.


Prenatal Diagnosis | 2008

Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth

Melinda J. Jasper; Jan Liebelt; Nicole D. Hussey

The risk of breast cancer associated with inheriting a BRCA1 mutation is extremely high, in addition, there is a 50% chance of transmitting this familial cancer mutation to any offspring.


Human Mutation | 2014

Three Different Cone Opsin Gene Array Mutational Mechanisms with Genotype–Phenotype Correlation and Functional Investigation of Cone Opsin Variants

Jessica C. Gardner; Gerald Liew; Yinghua Quan; Burcu Ermetal; Hisao Ueyama; Alice E. Davidson; Nele Schwarz; Naheed Kanuga; Ravinder Chana; Eamonn R. Maher; Andrew R. Webster; Graham E. Holder; Anthony G. Robson; Michael E. Cheetham; Jan Liebelt; Jonathan B Ruddle; Anthony T. Moore; Michel Michaelides; Alison J. Hardcastle

Mutations in the OPN1LW (L‐) and OPN1MW (M‐)cone opsin genes underlie a spectrum of cone photoreceptor defects from stationary loss of color vision to progressive retinal degeneration. Genotypes of 22 families with a range of cone disorders were grouped into three classes: deletions of the locus control region (LCR); missense mutation (p.Cys203Arg) in an L‐/M‐hybrid gene; and exon 3 single‐nucleotide polymorphism (SNP) interchange haplotypes in an otherwise normal gene array. Moderate‐to‐high myopia was observed in all mutation categories. Individuals with LCR deletions or p.Cys203Arg mutations were more likely to have nystagmus and poor vision, with disease progression in some p.Cys203Arg patients. Three disease‐associated exon 3 SNP haplotypes encoding LIAVA, LVAVA, or MIAVA were identified in our cohort. These patients were less likely to have nystagmus but more likely to show progression, with all patients over the age of 40 years having marked macular abnormalities. Previously, the haplotype LIAVA has been shown to result in exon 3 skipping. Here, we show that haplotypes LVAVA and MIAVA also result in aberrant splicing, with a residual low level of correctly spliced cone opsin. The OPN1LW/OPN1MW:c.532A>G SNP, common to all three disease‐associated haplotypes, appears to be principally responsible for this mutational mechanism.


Nature Neuroscience | 2017

Hotspots of missense mutation identify neurodevelopmental disorder genes and functional domains

Madeleine Geisheker; Gabriel Heymann; Tianyun Wang; Bradley P. Coe; Tychele N. Turner; Holly A.F. Stessman; Kendra Hoekzema; Malin Kvarnung; Marie Shaw; Kathryn Friend; Jan Liebelt; Christopher Barnett; Elizabeth Thompson; Eric Haan; Hui Guo; Britt Marie Anderlid; Ann Nordgren; Anna Lindstrand; Geert Vandeweyer; Antonino Alberti; Emanuela Avola; Mirella Vinci; Stefania Giusto; Tiziano Pramparo; Karen Pierce; Srinivasa Nalabolu; Jacob J. Michaelson; Zdenek Sedlacek; Gijs W.E. Santen; Hilde Peeters

Although de novo missense mutations have been predicted to account for more cases of autism than gene-truncating mutations, most research has focused on the latter. We identified the properties of de novo missense mutations in patients with neurodevelopmental disorders (NDDs) and highlight 35 genes with excess missense mutations. Additionally, 40 amino acid sites were recurrently mutated in 36 genes, and targeted sequencing of 20 sites in 17,688 patients with NDD identified 21 new patients with identical missense mutations. One recurrent site substitution (p.A636T) occurs in a glutamate receptor subunit, GRIA1. This same amino acid substitution in the homologous but distinct mouse glutamate receptor subunit Grid2 is associated with Lurcher ataxia. Phenotypic follow-up in five individuals with GRIA1 mutations shows evidence of specific learning disabilities and autism. Overall, we find significant clustering of de novo mutations in 200 genes, highlighting specific functional domains and synaptic candidate genes important in NDD pathology.


American Journal of Medical Genetics | 2013

Epilepsy with cognitive deficit and autism spectrum disorders: Prospective diagnosis by array CGH†‡§

Jillian Nicholl; Wendy Waters; Shanna Suwalski; Sue Brown; Yvonne Hull; Michael Harbord; John Entwistle; Suzanna Thompson; Damian Clark; Claire Pridmore; Eric Haan; Christopher Barnett; Lesley McGregor; Jan Liebelt; Elizabeth Thompson; Kathryn Friend; Sharon M. Bain; Sui Yu; John C. Mulley

The clinical significance of chromosomal microdeletions and microduplications was predicted based on their gene content, de novo or familial inheritance and accumulated knowledge recorded on public databases. A patient group comprised of 247 cases with epilepsy and its common co‐morbidities of developmental delay, intellectual disability, autism spectrum disorders, and congenital abnormalities was reviewed prospectively in a diagnostic setting using a standardized oligo‐array CGH platform. Seventy‐three (29.6%) had copy number variations (CNVs) and of these 73 cases, 27 (37.0%) had CNVs that were likely causative. These 27 cases comprised 10.9% of the 247 cases reviewed. The range of pathogenic CNVs associated with seizures was consistent with the existence of many genetic determinants for epilepsy.


Pathology | 2014

Cognitive deficit and autism spectrum disorders: prospective diagnosis by array CGH

Jillian Nicholl; Wendy Waters; John C. Mulley; Shanna Suwalski; Sue Brown; Yvonne Hull; Christopher Barnett; Eric Haan; Elizabeth Thompson; Jan Liebelt; Lesley McGregor; Michael Harbord; John Entwistle; Chris Munt; Dierdre White; Anthony Chitti; David Baulderstone; David Ketteridge; Kathryn Friend; Sharon M. Bain; Y.u. Sui

Summary The aim of this study was to determine prospectively the frequency of pathogenic chromosomal microdeletions and microduplications in a large group of referred patients with developmental delay (DD), intellectual disability (ID) or autism spectrum disorders (ASD) within a genetic diagnostic service. First tier testing was applied using a standardised oligo-array comparative genomic hybridization (CGH) platform, replacing conventional cytogenetic testing that would have been used in the past. Copy number variants (CNVs) found to be responsible for the clinical condition on the request form could all be subdivided into three groups: well established pathogenic microdeletion/microduplication/aneuploidy syndromes, predicted pathogenic CNVs as interpreted by the laboratory, and recently established pathogenic disease susceptibility CNVs. Totalled from these three groups, with CNVs of uncertain significance excluded, detection rates were: DD (13.0%), ID (15.6%), ASD (2.3%), ASD with DD (8.2%), ASD with ID (12.7%) and unexplained epilepsy with DD, ID and ASD (10.9%). The greater diagnostic sensitivity arising from routine application of array CGH, compared with previously used conventional cytogenetics, outweighs the interpretative issues for the reporting laboratory and referring clinician arising from detection of CNVs of uncertain significance. Precise determination of any previously hidden molecular defect responsible for the patients condition is translated to improved genetic counselling.

Collaboration


Dive into the Jan Liebelt's collaboration.

Top Co-Authors

Avatar

Kathryn Friend

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Eric Haan

University of Adelaide

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jozef Gecz

University of Adelaide

View shared research outputs
Top Co-Authors

Avatar

Jillian Nicholl

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Sharon M. Bain

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Sui Yu

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Marie Shaw

University of Adelaide

View shared research outputs
Researchain Logo
Decentralizing Knowledge